DK2943192T3 - Fremgangsmåder til behandling af pancreascancer, hvilke fremgangsmåder omfatter paclitaxel og gemcitabin - Google Patents
Fremgangsmåder til behandling af pancreascancer, hvilke fremgangsmåder omfatter paclitaxel og gemcitabin Download PDFInfo
- Publication number
- DK2943192T3 DK2943192T3 DK14737791.5T DK14737791T DK2943192T3 DK 2943192 T3 DK2943192 T3 DK 2943192T3 DK 14737791 T DK14737791 T DK 14737791T DK 2943192 T3 DK2943192 T3 DK 2943192T3
- Authority
- DK
- Denmark
- Prior art keywords
- procedures
- pancreascancer
- gemcitabine
- treatment
- include paclitaxel
- Prior art date
Links
Classifications
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K9/00—Medicinal preparations characterised by special physical form
- A61K9/48—Preparations in capsules, e.g. of gelatin, of chocolate
- A61K9/50—Microcapsules having a gas, liquid or semi-solid filling; Solid microparticles or pellets surrounded by a distinct coating layer, e.g. coated microspheres, coated drug crystals
- A61K9/51—Nanocapsules; Nanoparticles
- A61K9/5107—Excipients; Inactive ingredients
- A61K9/513—Organic macromolecular compounds; Dendrimers
- A61K9/5169—Proteins, e.g. albumin, gelatin
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/335—Heterocyclic compounds having oxygen as the only ring hetero atom, e.g. fungichromin
- A61K31/337—Heterocyclic compounds having oxygen as the only ring hetero atom, e.g. fungichromin having four-membered rings, e.g. taxol
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/70—Carbohydrates; Sugars; Derivatives thereof
- A61K31/7042—Compounds having saccharide radicals and heterocyclic rings
- A61K31/7052—Compounds having saccharide radicals and heterocyclic rings having nitrogen as a ring hetero atom, e.g. nucleosides, nucleotides
- A61K31/706—Compounds having saccharide radicals and heterocyclic rings having nitrogen as a ring hetero atom, e.g. nucleosides, nucleotides containing six-membered rings with nitrogen as a ring hetero atom
- A61K31/7064—Compounds having saccharide radicals and heterocyclic rings having nitrogen as a ring hetero atom, e.g. nucleosides, nucleotides containing six-membered rings with nitrogen as a ring hetero atom containing condensed or non-condensed pyrimidines
- A61K31/7068—Compounds having saccharide radicals and heterocyclic rings having nitrogen as a ring hetero atom, e.g. nucleosides, nucleotides containing six-membered rings with nitrogen as a ring hetero atom containing condensed or non-condensed pyrimidines having oxo groups directly attached to the pyrimidine ring, e.g. cytidine, cytidylic acid
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K9/00—Medicinal preparations characterised by special physical form
- A61K9/0012—Galenical forms characterised by the site of application
- A61K9/0019—Injectable compositions; Intramuscular, intravenous, arterial, subcutaneous administration; Compositions to be administered through the skin in an invasive manner
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
- A61P1/18—Drugs for disorders of the alimentary tract or the digestive system for pancreatic disorders, e.g. pancreatic enzymes
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P35/00—Antineoplastic agents
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P35/00—Antineoplastic agents
- A61P35/04—Antineoplastic agents specific for metastasis
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
Landscapes
- Health & Medical Sciences (AREA)
- Life Sciences & Earth Sciences (AREA)
- Chemical & Material Sciences (AREA)
- Animal Behavior & Ethology (AREA)
- Medicinal Chemistry (AREA)
- Pharmacology & Pharmacy (AREA)
- General Health & Medical Sciences (AREA)
- Public Health (AREA)
- Veterinary Medicine (AREA)
- Epidemiology (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Engineering & Computer Science (AREA)
- Organic Chemistry (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- General Chemical & Material Sciences (AREA)
- Chemical Kinetics & Catalysis (AREA)
- Optics & Photonics (AREA)
- Nanotechnology (AREA)
- Biomedical Technology (AREA)
- Physics & Mathematics (AREA)
- Molecular Biology (AREA)
- Oncology (AREA)
- Dermatology (AREA)
- Communicable Diseases (AREA)
- Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
- Medicinal Preparation (AREA)
- Proteomics, Peptides & Aminoacids (AREA)
- Zoology (AREA)
- Gastroenterology & Hepatology (AREA)
- Immunology (AREA)
- Inorganic Chemistry (AREA)
Applications Claiming Priority (4)
Application Number | Priority Date | Filing Date | Title |
---|---|---|---|
US201361751820P | 2013-01-11 | 2013-01-11 | |
US201361752355P | 2013-01-14 | 2013-01-14 | |
US13/794,480 US9511046B2 (en) | 2013-01-11 | 2013-03-11 | Methods of treating pancreatic cancer |
PCT/US2014/011145 WO2014110443A1 (en) | 2013-01-11 | 2014-01-10 | Methods of treating pancreatic cancer |
Publications (1)
Publication Number | Publication Date |
---|---|
DK2943192T3 true DK2943192T3 (da) | 2021-07-05 |
Family
ID=51165317
Family Applications (1)
Application Number | Title | Priority Date | Filing Date |
---|---|---|---|
DK14737791.5T DK2943192T3 (da) | 2013-01-11 | 2014-01-10 | Fremgangsmåder til behandling af pancreascancer, hvilke fremgangsmåder omfatter paclitaxel og gemcitabin |
Country Status (24)
Country | Link |
---|---|
US (3) | US9511046B2 (da) |
EP (1) | EP2943192B9 (da) |
JP (3) | JP6342918B2 (da) |
KR (1) | KR102205710B1 (da) |
CN (2) | CN105025893A (da) |
AU (1) | AU2013203699B2 (da) |
BR (1) | BR112015016681A8 (da) |
CA (1) | CA2897589C (da) |
CY (1) | CY1124273T1 (da) |
DK (1) | DK2943192T3 (da) |
ES (1) | ES2878145T3 (da) |
HK (1) | HK1216853A1 (da) |
HR (1) | HRP20211062T1 (da) |
HU (1) | HUE056612T2 (da) |
IL (2) | IL239739A0 (da) |
LT (1) | LT2943192T (da) |
MX (1) | MX2015008898A (da) |
NZ (2) | NZ734971A (da) |
PL (1) | PL2943192T3 (da) |
PT (1) | PT2943192T (da) |
RS (1) | RS62076B1 (da) |
SI (1) | SI2943192T1 (da) |
WO (1) | WO2014110443A1 (da) |
ZA (1) | ZA201504877B (da) |
Families Citing this family (32)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
TR200502189T1 (tr) | 2002-12-09 | 2007-01-22 | American Bioscience, Inc. | Kompozisyonlar ve farmakolojik etken maddelerin aktarımı için yöntemler. |
MX2007009960A (es) | 2005-02-18 | 2008-03-11 | Abraxis Bioscience Inc | Combinaciones y metodos de administracion de agentes terapeuticos y terapia de combinacion. |
US8735394B2 (en) | 2005-02-18 | 2014-05-27 | Abraxis Bioscience, Llc | Combinations and modes of administration of therapeutic agents and combination therapy |
EP1931321B1 (en) | 2005-08-31 | 2018-12-26 | Abraxis BioScience, LLC | Compositions comprising poorly water soluble pharmaceutical agents and antimicrobial agents |
WO2008076373A1 (en) | 2006-12-14 | 2008-06-26 | Abraxis Bioscience, Llc | Breast cancer therapy based on hormone receptor status with nanoparticles comprising taxane |
CA2689914C (en) * | 2007-06-01 | 2016-08-16 | Abraxis Bioscience, Llc | Use of protein-bound taxane nanoparticles in the treatment of recurrent gynecological cancers |
BRPI1012525A2 (pt) | 2009-04-15 | 2018-07-10 | Abraxis Bioscience, Llc. | composições de nanopatículas isentas de príons e métodos para sua fabricação |
MX359413B (es) | 2010-03-26 | 2018-09-27 | Abraxis Bioscience Llc | Metodos de tratamiento de carcinoma hepatocelular. |
CA2794147A1 (en) | 2010-03-29 | 2011-10-06 | Abraxis Bioscience, Llc | Use of a composition comprising nanoparticles comprising a taxane and an albumin to improve uptake of chemotherapeutics by tumors and for treating a cancer that is highly fibrotic and/or has a dense stroma |
NZ602385A (en) | 2010-03-29 | 2014-08-29 | Abraxis Bioscience Llc | Methods of treating cancer |
CN103140225A (zh) | 2010-06-04 | 2013-06-05 | 阿布拉科斯生物科学有限公司 | 治疗胰腺癌的方法 |
MY166014A (en) * | 2010-06-07 | 2018-05-21 | Abraxis Bioscience Llc | Combination therapy methods for treating proliferative diseases |
JP6038123B2 (ja) | 2011-04-28 | 2016-12-07 | アブラクシス バイオサイエンス, エルエルシー | ナノ粒子組成物の脈管内送達およびそれらの使用 |
PT2790675T (pt) | 2011-12-14 | 2019-09-23 | Abraxis Bioscience Llc | Utilização de excipientes poliméricos para a liofilização ou a congelação de partículas |
US9149455B2 (en) | 2012-11-09 | 2015-10-06 | Abraxis Bioscience, Llc | Methods of treating melanoma |
US9511046B2 (en) | 2013-01-11 | 2016-12-06 | Abraxis Bioscience, Llc | Methods of treating pancreatic cancer |
EP2968254B1 (en) | 2013-03-12 | 2020-04-22 | Abraxis BioScience, LLC | Methods of treating lung cancer |
ES2881851T3 (es) | 2013-03-14 | 2021-11-30 | Abraxis Bioscience Llc | Métodos para tratar el cáncer de vejiga |
US10705070B1 (en) | 2015-03-05 | 2020-07-07 | Abraxis Bioscience, Llc | Methods of assessing suitability of use of pharmaceutical compositions of albumin and poorly water soluble drug |
US10527604B1 (en) | 2015-03-05 | 2020-01-07 | Abraxis Bioscience, Llc | Methods of assessing suitability of use of pharmaceutical compositions of albumin and paclitaxel |
EP3302431B1 (en) | 2015-06-04 | 2020-11-11 | Crititech, Inc. | Taxane particles and their use |
ES2897991T3 (es) | 2015-06-29 | 2022-03-03 | Abraxis Bioscience Llc | Nanopartículas que comprenden sirolimus y una albúmina para uso en tratamiento de tumores de células epitelioides |
US10925852B2 (en) * | 2015-06-30 | 2021-02-23 | The Trustees Of Columbia University In The City Of New York | Talc-bound compositions and uses thereof |
CN109475492B (zh) | 2016-04-04 | 2022-04-29 | 克里蒂泰克公司 | 实体肿瘤治疗方法 |
EP3595717A1 (en) * | 2017-03-17 | 2020-01-22 | Imclone, LLC | Combination therapy for pancreatic cancer |
JP2020523285A (ja) | 2017-06-09 | 2020-08-06 | クリチテック,インコーポレイテッド | 抗腫瘍粒子の嚢胞内注入による上皮嚢胞の治療 |
SG11201909837YA (en) | 2017-06-14 | 2019-11-28 | Crititech Inc | Methods for treating lung disorders |
CN111278436A (zh) | 2017-10-03 | 2020-06-12 | 克里蒂泰克公司 | 局部递送抗肿瘤颗粒与全身递送免疫治疗剂相结合用于治疗癌症 |
CN112188892A (zh) | 2018-03-20 | 2021-01-05 | 阿布拉科斯生物科学有限公司 | 通过mTOR抑制剂和白蛋白的纳米颗粒的施用治疗中枢神经系统障碍的方法 |
GB201908352D0 (en) * | 2019-06-11 | 2019-07-24 | Innovation Ulster Ltd | Sonodynamic therapy |
KR20220106758A (ko) | 2019-10-28 | 2022-07-29 | 아브락시스 바이오사이언스, 엘엘씨 | 알부민 및 라파마이신의 제약 조성물 |
EP4100035A1 (en) * | 2020-02-04 | 2022-12-14 | Swedish Orphan Biovitrum AB (publ) | Pdac treatment regimen |
Family Cites Families (72)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
US6537579B1 (en) | 1993-02-22 | 2003-03-25 | American Bioscience, Inc. | Compositions and methods for administration of pharmacologically active compounds |
US20030068362A1 (en) | 1993-02-22 | 2003-04-10 | American Bioscience, Inc. | Methods and formulations for the delivery of pharmacologically active agents |
US5650156A (en) | 1993-02-22 | 1997-07-22 | Vivorx Pharmaceuticals, Inc. | Methods for in vivo delivery of nutriceuticals and compositions useful therefor |
WO1999000113A1 (en) | 1997-06-27 | 1999-01-07 | Vivorx Pharmaceuticals, Inc. | Novel formulations of pharmacological agents, methods for the preparation thereof and methods for the use thereof |
US6753006B1 (en) | 1993-02-22 | 2004-06-22 | American Bioscience, Inc. | Paclitaxel-containing formulations |
US5439686A (en) | 1993-02-22 | 1995-08-08 | Vivorx Pharmaceuticals, Inc. | Methods for in vivo delivery of substantially water insoluble pharmacologically active agents and compositions useful therefor |
US5997904A (en) | 1993-02-22 | 1999-12-07 | American Bioscience, Inc. | Total nutrient admixtures as stable multicomponent liquids or dry powders and methods for the preparation thereof |
US6096331A (en) | 1993-02-22 | 2000-08-01 | Vivorx Pharmaceuticals, Inc. | Methods and compositions useful for administration of chemotherapeutic agents |
US6528067B1 (en) | 1993-02-22 | 2003-03-04 | American Bioscience, Inc. | Total nutrient admixtures as stable multicomponent liquids or dry powders and methods for the preparation thereof |
PT693924E (pt) | 1993-02-22 | 2004-09-30 | American Biosciences | Processos para administracao (in vivo) de substancias biologicas e composicoes utilizadas nestes processos |
US5362478A (en) | 1993-03-26 | 1994-11-08 | Vivorx Pharmaceuticals, Inc. | Magnetic resonance imaging with fluorocarbons encapsulated in a cross-linked polymeric shell |
US6749868B1 (en) | 1993-02-22 | 2004-06-15 | American Bioscience, Inc. | Protein stabilized pharmacologically active agents, methods for the preparation thereof and methods for the use thereof |
US5916596A (en) | 1993-02-22 | 1999-06-29 | Vivorx Pharmaceuticals, Inc. | Protein stabilized pharmacologically active agents, methods for the preparation thereof and methods for the use thereof |
US6565842B1 (en) | 1995-06-07 | 2003-05-20 | American Bioscience, Inc. | Crosslinkable polypeptide compositions |
US8137684B2 (en) | 1996-10-01 | 2012-03-20 | Abraxis Bioscience, Llc | Formulations of pharmacological agents, methods for the preparation thereof and methods for the use thereof |
US20030199425A1 (en) | 1997-06-27 | 2003-10-23 | Desai Neil P. | Compositions and methods for treatment of hyperplasia |
US8853260B2 (en) | 1997-06-27 | 2014-10-07 | Abraxis Bioscience, Llc | Formulations of pharmacological agents, methods for the preparation thereof and methods for the use thereof |
WO2000064437A1 (en) | 1999-04-22 | 2000-11-02 | American Biosciences, Inc. | Long term administration of pharmacologically active agents |
EP1178786A4 (en) | 1999-05-21 | 2006-03-01 | American Bioscience Inc | PHARMACOLOGICALLY ACTIVE PROTEIN STABILIZING AGENTS; METHODS OF MANUFACTURE AND METHODS OF USE |
ITMI20001107A1 (it) | 2000-05-18 | 2001-11-18 | Acs Dobfar Spa | Metodo per il trattamento di tumori solici mediante microparticelle di albumina incorporanti paclitaxel |
ITMI20020681A1 (it) * | 2002-03-29 | 2003-09-29 | Acs Dobfar Spa | Procedimento per la produzione di nanoparticelle di paclitaxel ed albumina |
TR200502189T1 (tr) | 2002-12-09 | 2007-01-22 | American Bioscience, Inc. | Kompozisyonlar ve farmakolojik etken maddelerin aktarımı için yöntemler. |
KR20050095826A (ko) | 2002-12-09 | 2005-10-04 | 아메리칸 바이오사이언스, 인크. | 약리학적 물질의 조성물 및 그 전달방법 |
AU2012201568B2 (en) | 2005-02-18 | 2014-07-31 | Abraxis Bioscience, Llc | Combinations and modes of administration of therapeutic agents and combination therapy |
MX2007009960A (es) | 2005-02-18 | 2008-03-11 | Abraxis Bioscience Inc | Combinaciones y metodos de administracion de agentes terapeuticos y terapia de combinacion. |
US20070166388A1 (en) | 2005-02-18 | 2007-07-19 | Desai Neil P | Combinations and modes of administration of therapeutic agents and combination therapy |
US8735394B2 (en) | 2005-02-18 | 2014-05-27 | Abraxis Bioscience, Llc | Combinations and modes of administration of therapeutic agents and combination therapy |
AU2006242540A1 (en) * | 2005-04-29 | 2006-11-09 | Kosan Biosciences Incorporated | Method of treating multiple myeloma using 17-AAG of 17-AG of a prodrug of either |
NZ592132A (en) | 2005-08-31 | 2012-12-21 | Abraxis Bioscience Llc | Composition comprising nanoparticles of docitaxel and a citrate |
EP1931321B1 (en) | 2005-08-31 | 2018-12-26 | Abraxis BioScience, LLC | Compositions comprising poorly water soluble pharmaceutical agents and antimicrobial agents |
JP2007297339A (ja) * | 2006-04-29 | 2007-11-15 | Torii Yakuhin Kk | 癌を治療又は検査するための医薬 |
EP2056812A1 (en) | 2006-08-31 | 2009-05-13 | Abraxis BioScience, LLC | Methods of inhibiting angiogenesis and treating angiogenesis-associated diseases |
WO2008076373A1 (en) | 2006-12-14 | 2008-06-26 | Abraxis Bioscience, Llc | Breast cancer therapy based on hormone receptor status with nanoparticles comprising taxane |
KR101943230B1 (ko) | 2007-03-07 | 2019-01-28 | 아브락시스 바이오사이언스, 엘엘씨 | 항암제로서 라파마이신 및 알부민을 포함하는 나노입자 |
EP3326630A3 (en) | 2007-05-03 | 2018-08-29 | Abraxis BioScience, LLC | Methods and compositions for treating pulmonary hypertension |
CA2689914C (en) | 2007-06-01 | 2016-08-16 | Abraxis Bioscience, Llc | Use of protein-bound taxane nanoparticles in the treatment of recurrent gynecological cancers |
MX2010011165A (es) | 2008-04-10 | 2011-02-22 | Abraxis Bioscience Llc | Composiciones de derivados de taxano hidrofobos y sus usos. |
KR20150136137A (ko) | 2008-04-10 | 2015-12-04 | 아브락시스 바이오사이언스, 엘엘씨 | 소수성 탁산 유도체의 조성물 및 그의 용도 |
RU2556129C2 (ru) * | 2008-04-11 | 2015-07-10 | Сиэтл Дженетикс, Инк. | Диагностика и лечение злокачественных опухолей поджелудочной железы, яичников и других злокачественных опухолей |
MX2011006167A (es) | 2008-12-11 | 2011-07-28 | Abraxis Bioscience Llc | Combinaciones y modos de administracion de agentes terapeuticos y terapia de combinacion. |
GB0900555D0 (en) | 2009-01-14 | 2009-02-11 | Topotarget As | New methods |
CA2755121A1 (en) | 2009-03-13 | 2010-09-16 | Neil P. Desai | Combination therapy with thiocolchicine derivatives |
BRPI1014160A2 (pt) | 2009-04-10 | 2015-08-25 | Abraxis Bioscience Llc | Formulações de nanopartículas e aplicações das mesmas |
BRPI1012525A2 (pt) | 2009-04-15 | 2018-07-10 | Abraxis Bioscience, Llc. | composições de nanopatículas isentas de príons e métodos para sua fabricação |
KR20120024794A (ko) * | 2009-05-28 | 2012-03-14 | 아브락시스 바이오사이언스, 엘엘씨 | 화학요법에 대한 반응을 예측하는 2 항-sparc 항체의 용도 |
KR20120053052A (ko) | 2009-08-25 | 2012-05-24 | 아브락시스 바이오사이언스, 엘엘씨 | 헤지호그 억제제 및 탁산의 나노입자 조성물로의 조합 요법 |
JP2011079788A (ja) * | 2009-10-08 | 2011-04-21 | Oita Univ | 膵癌に対する選択的膵動脈制癌剤注入療法と全身化学療法との併用療法、およびそれに使用する膵癌治療薬 |
SG10201500013SA (en) * | 2010-01-05 | 2015-03-30 | Vascular Biogenics Ltd | Methods for use of a specific anti-angiogenic adenoviral agent |
MX359413B (es) | 2010-03-26 | 2018-09-27 | Abraxis Bioscience Llc | Metodos de tratamiento de carcinoma hepatocelular. |
CA2794147A1 (en) | 2010-03-29 | 2011-10-06 | Abraxis Bioscience, Llc | Use of a composition comprising nanoparticles comprising a taxane and an albumin to improve uptake of chemotherapeutics by tumors and for treating a cancer that is highly fibrotic and/or has a dense stroma |
NZ602385A (en) | 2010-03-29 | 2014-08-29 | Abraxis Bioscience Llc | Methods of treating cancer |
EP2552453A2 (en) | 2010-03-30 | 2013-02-06 | Clavis Pharma ASA | Methods and compositions for treating or ameliorating cancer using gemcitabine-5'-elaidate |
NZ708506A (en) | 2010-06-02 | 2016-08-26 | Abraxis Bioscience Llc | Methods of treating bladder cancer |
CN103140225A (zh) | 2010-06-04 | 2013-06-05 | 阿布拉科斯生物科学有限公司 | 治疗胰腺癌的方法 |
MY166014A (en) | 2010-06-07 | 2018-05-21 | Abraxis Bioscience Llc | Combination therapy methods for treating proliferative diseases |
JP6038123B2 (ja) | 2011-04-28 | 2016-12-07 | アブラクシス バイオサイエンス, エルエルシー | ナノ粒子組成物の脈管内送達およびそれらの使用 |
PT2790675T (pt) | 2011-12-14 | 2019-09-23 | Abraxis Bioscience Llc | Utilização de excipientes poliméricos para a liofilização ou a congelação de partículas |
US9149455B2 (en) | 2012-11-09 | 2015-10-06 | Abraxis Bioscience, Llc | Methods of treating melanoma |
US20140186447A1 (en) | 2012-12-28 | 2014-07-03 | Abraxis Bioscience, Llc | Nanoparticle compositions of albumin and paclitaxel |
US20140199405A1 (en) | 2013-01-11 | 2014-07-17 | Abraxis Bioscience, Llc | Method for treating cancer based on mutation status of k-ras |
US9511046B2 (en) | 2013-01-11 | 2016-12-06 | Abraxis Bioscience, Llc | Methods of treating pancreatic cancer |
US20140199404A1 (en) | 2013-01-11 | 2014-07-17 | Abraxis Bioscience, Llc | Method for treating cancer based on level of a nucleoside transporter |
KR102148551B1 (ko) | 2013-02-11 | 2020-08-26 | 아브락시스 바이오사이언스, 엘엘씨 | 흑색종을 치료하는 방법 |
EP2968254B1 (en) | 2013-03-12 | 2020-04-22 | Abraxis BioScience, LLC | Methods of treating lung cancer |
EP2968253A4 (en) | 2013-03-13 | 2016-11-02 | Abraxis Bioscience Llc | METHODS OF TREATING PEDIATRIC SOLID TUMOR |
ES2881851T3 (es) | 2013-03-14 | 2021-11-30 | Abraxis Bioscience Llc | Métodos para tratar el cáncer de vejiga |
WO2015157120A1 (en) | 2014-04-06 | 2015-10-15 | Abraxis Bioscience, Llc | Combination therapy comprising nanoparticles of a taxane and albumin with abt-263 in methods for treating cancer |
US20180064679A1 (en) | 2015-03-05 | 2018-03-08 | Abraxis Bioscience, Llc | Method for treating cancer based on level of glucocorticoid receptor |
MX2017016492A (es) | 2015-06-29 | 2018-08-16 | Abraxis Bioscience Llc | Metodos para tratar tumores solidos usando terapia de combinacion de nanoparticula del inhibidor del objetivo mamifero de la rapamicina (mtor). |
MX2017016519A (es) | 2015-06-29 | 2018-08-16 | Abraxis Bioscience Llc | Biomarcadores para composiciones de nanoparticulas. |
ES2897991T3 (es) | 2015-06-29 | 2022-03-03 | Abraxis Bioscience Llc | Nanopartículas que comprenden sirolimus y una albúmina para uso en tratamiento de tumores de células epitelioides |
US20170181988A1 (en) | 2015-12-23 | 2017-06-29 | Cipla Limited | Methods for the treatment of bladder cancer |
-
2013
- 2013-03-11 US US13/794,480 patent/US9511046B2/en active Active
- 2013-04-11 AU AU2013203699A patent/AU2013203699B2/en active Active
-
2014
- 2014-01-10 JP JP2015552834A patent/JP6342918B2/ja active Active
- 2014-01-10 PL PL14737791T patent/PL2943192T3/pl unknown
- 2014-01-10 BR BR112015016681A patent/BR112015016681A8/pt not_active Application Discontinuation
- 2014-01-10 LT LTEP14737791.5T patent/LT2943192T/lt unknown
- 2014-01-10 NZ NZ734971A patent/NZ734971A/en unknown
- 2014-01-10 HU HUE14737791A patent/HUE056612T2/hu unknown
- 2014-01-10 CN CN201480013217.4A patent/CN105025893A/zh active Pending
- 2014-01-10 ES ES14737791T patent/ES2878145T3/es active Active
- 2014-01-10 KR KR1020157021320A patent/KR102205710B1/ko active IP Right Review Request
- 2014-01-10 RS RS20210823A patent/RS62076B1/sr unknown
- 2014-01-10 PT PT147377915T patent/PT2943192T/pt unknown
- 2014-01-10 SI SI201431853T patent/SI2943192T1/sl unknown
- 2014-01-10 NZ NZ630230A patent/NZ630230A/en unknown
- 2014-01-10 CN CN201910067315.0A patent/CN109793728A/zh active Pending
- 2014-01-10 WO PCT/US2014/011145 patent/WO2014110443A1/en active Application Filing
- 2014-01-10 MX MX2015008898A patent/MX2015008898A/es unknown
- 2014-01-10 DK DK14737791.5T patent/DK2943192T3/da active
- 2014-01-10 HR HRP20211062TT patent/HRP20211062T1/hr unknown
- 2014-01-10 CA CA2897589A patent/CA2897589C/en active Active
- 2014-01-10 EP EP14737791.5A patent/EP2943192B9/en not_active Revoked
-
2015
- 2015-07-01 IL IL239739A patent/IL239739A0/en unknown
- 2015-07-07 ZA ZA2015/04877A patent/ZA201504877B/en unknown
-
2016
- 2016-04-28 HK HK16104890.5A patent/HK1216853A1/zh unknown
- 2016-10-06 US US15/287,613 patent/US9855220B2/en active Active
-
2017
- 2017-11-21 US US15/820,022 patent/US10328031B2/en active Active
-
2018
- 2018-02-21 JP JP2018028611A patent/JP6697017B2/ja active Active
-
2019
- 2019-02-27 JP JP2019033910A patent/JP2019081790A/ja active Pending
-
2020
- 2020-02-26 IL IL272905A patent/IL272905A/en unknown
-
2021
- 2021-06-30 CY CY20211100585T patent/CY1124273T1/el unknown
Also Published As
Similar Documents
Publication | Publication Date | Title |
---|---|---|
DK2943192T3 (da) | Fremgangsmåder til behandling af pancreascancer, hvilke fremgangsmåder omfatter paclitaxel og gemcitabin | |
DK3785717T3 (da) | Fremgangsmåder til behandling af coronaviridae-infektioner | |
DK3288581T3 (da) | Fremgangsmåde til behandling af cancer | |
DK3035926T3 (da) | Forbindelser og fremgangsmåder til behandling af en epilepsilidelse | |
DK3354282T3 (da) | Glycan-terapeutiske midler og relaterede fremgangsmåder deraf | |
DK3380101T3 (da) | Eif4-a-inhiberende forbindelser og fremgangsmåder relateret dertil | |
DK2986304T3 (da) | Farmaceutisk sammensætning, fremgangsmåder til behandling og anvendelser deraf. | |
DK3102673T3 (da) | Fremgangsmåder og sammensætninger til behandling af beta-talassæmi | |
DK3778595T3 (da) | Pancreatitisbehandling | |
DK3030323T3 (da) | Kdm1a-inhibitorer til behandlingen af sygdom | |
DK3076976T3 (da) | Fremgangsmåder til behandling af cancer | |
DK3685848T3 (da) | Sammensætninger og fremgangsmåder til behandling af pulmonal hypertension | |
DK3007695T3 (da) | Sammensætninger og fremgangsmåder til behandling af anæmi | |
DK2861273T3 (da) | Anvendelse af heparin og kulhydrater til behandling af cancer. | |
DK3238707T3 (da) | Sammensætninger og fremgangsmåder til behandling af intestinal hyperpermeabilitet | |
DK2967049T3 (da) | Metoder, forbindelser og sammensætninger til behandlingen af angiotensin relaterede sygdomme | |
DK3265087T3 (da) | Fremgangsmåde til behandling med tradipitant | |
DK3103715T3 (da) | Styreindretning og styringsfremgangsmåde dertil | |
DK3374497T3 (da) | Modificerede makrofager til anvendelse i behandlingen af kræft | |
DK2994157T3 (da) | Tafa4-forbindelser og anvendelser deraf til behandling af smerte | |
DK3200748T3 (da) | Sammensætninger og fremgangsmåder til behandling og profylakse af infektioner på operationssted | |
DK3191103T3 (da) | Sammensætninger og fremgangsmåder til behandling af præcancerøse hudlæsioner | |
DK3389669T3 (da) | Triterpensaponinvarianter, syntesefremgangsmåder og anvendelse deraf | |
DK3373937T3 (da) | Anti-cd22-antistof-maytansin-konjugater og fremgangsmåder til anvendelse deraf | |
DK3308781T3 (da) | Antihypertensivt middel |